Abstract. The nephrotic syndrome is frequently associated with hyperlipidaemia and hyperfibrinogenaemia, leading to an increased coronary and thrombotic risk, wh ich may be enhanced by high lipoprotein (a) [Lp(a)] concentrations.
Introduction
Plasma concentrations of cholesterol and triglycerides are frequently elevated in patients with nephrotic syndrome. This type of hyperlipoproteinaemia is mainly caused by an increase in atherogenic lipoproteins containing apolipoprotein B-100 as major apolipoprotein [I] . Recent observations have indicated that some patients with nephrotic syndrome show an increase in lipoprotein (a) [(Lp(a)], a lipoprotein particle associated with elevated coronary heart disease (CHO) risk [2] [3] [4] . Correspondence: J. Thiery 
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The elucidation of the structure of apo(a), the characteristic apoprotein of the lipoprotein Lp(a), has revealed a high homology to kringle 4 domains of human plasminogen [5] . This similarity provides a tentative link between the plasma lipoproteins and the clotting system [6] . Lp(a) plasma levels are under tight genetic control, independent of low-density lipoprotein (LOL) plasma concentrations and refractory to dietary or drug treatment [7] . Utermann et al. [8] have shown an inverse correlation between the size of apo(a) isoforms, that is the number of repeated kringle 4 domains, and the plasma Lp(a) concentration.
We measured lipoprotein parameters in hospitalized patients with longstanding nephrotic syndrome. One of these patients was also suffering from severe coronary artery disease, and had an extremely elevated level of Lp(a). Plasma lipoproteins were followed in detail in this patient in order to elucidate the underIying cause of the elevated Lp(a) levels.
The patient was treated with plasma apheresis using the heparin-media ted extracorporeal LOL precipitation (HELP) procedure, which effectively eliminates plasma LOL, Lp(a) and fibrinogen [9, 10] . We followed the kinetics of post-apheresis return of LOL, Lp(a) and fibrinogen to calculate their synthetic and fractional catabolic rates [li] .
Methods

Clinical follOlr-up of the patient
In Oecember 1979 at 42 years of age, the patient (D.K.) underwent a myocardial infarction. At this time two coronary risk factors were noted: smoking of 20 cigarettes per day for about 10 years and a mild hypercholesterolaemia (total cholesterol 250 mg dL -I,
The patient stopped smoking after the heart attack. During the next 10 years, plasma cholesterol concentrations ranged between 200 and 250mgdL-I (5·2-6·5mmoIL-I). In November 1989, the patient was diagnosed as having perimyocarditis accompanied by a small pericardial effusion. A few months later, he developed © 1996 Blackwell Science Ltd NEPHROTIC SYNDROME AND LIPOPROTEIN(a) 317 tibial oedema accompanied by accelerated erythrocyte sedimentation rate, decreased total serum protein concentration (5IgL-I) and marked proteinuria (12'7 gday-I).
Kidney biopsy showed diffuse membranous glomerulonephritis.
Plasma cholesterol concentrations were above 400mgdL -I (l0'4mmol L-I), and triglyceride concentrations ranged between 136 (1'6 mmol L-I) and 367 mg dl (4'2 mmol L-I). Standard treatment with chlorambucil and prednisolone, which was continued for 1·5 years, decreased proteinuria «8Agday-l) and the tibial oedema disappeared. No tumour-associated antigens were present in serum and serological tests for viral infections were negative.
In April 1992, the patient was referred to our institute for further investigation. but revealed elevated Lp(a) concentrations of60 and 70mgdL-1 (0'6 and 0·7gL-I). His wife is normocholesterolaemic and her Lp(a) concentration is 2'9mgdL-I (0·029gL-I).
Chemical and lipoprotein determinations
Clinical chemistry and immunological indices were measured by standard techniques. Plasma cholesterol and triglycerides were measured using enzymatic test kits from Boehringer (Mannheim, Germany). Serum LDL-cholesterol was quantified by a direct precipitation procedure (Immuno, Heidelberg, Germany) [9] . As both LDL and Lp(a) are precipitated by this procedure, the true LDL-cholesterol value was calculated by subtracting the corresponding Lp(a) concentration multiplied by 0,3 [Lp(a)-cholesterol] [3] . The concentration of serum Lp(a) was determined by Laurell electrophoresis using commercial antibodies from Immuno. Apo(a) isoforms were characterized by Dr Uterman, University of Innsbruck, Austria.
HDL-cholesterol was measured enzymatically (Boehringer Mannheim) after initial precipitation of Table I (mmol VI). 9 F=O'OOI (gday-'). course of plasma Lp(a), albumin and urinary pro tein is shown in Fig. 1 . Fibrinogen remained elevated above 400 mgdL-1 (0'4 gdL -I). The apoprotein(a) isoform patterns are shown in Table 2 . The patient and his daughter displayed the same small isoform S2 and a common allele 10. The effects of the HELP apheresis (J hand 7 days post apheresis) on the elimination of LDL, Lp(a) and fibrinogen are presented in Table 3 . The postapheresis return ofLDL, Lp(a) and fibrinogen to baseline levels in the nephrotic patient, FH heterozygote and normolipidaemic control are illustrated in Fig. 2 . Post-apheresis return of LDL-cholesterol and Lp(a) in the nephrotic was delayed as compared with the control but was similiar to hypercholesterolaemic subjects. CaIculation of turnover rates for LDLcholesterol, Lp(a) and fibrinogen are presented in Table 4 . The FCR for LDL-cholesterol was greatly reduced in our nephrotic patient, but was similar to the FH heterozygote patient. In contrast, absolute catabolic rates (ACRs) for the normolipidaemic
Post apheresis reacC1l11111lation of LDL. Lp( a) and fibrinogen
A single HELP apheresis was performed in July 1992 to prove the efficacy of this procedure in removal of plasma Lp(a) and to determine the reaccumulation rates of LDL, Lp(a) and plasma fibrinogen in patients with nephrotic syndrome [9, 10] . The apparatus used, a Plasmat Secura, was provided by B. Braun (Melsungen, Germany). A total of 3 L of plasma was treated. Plasma and serum sampIes were obtained directly before and after the HELP apheresis. During the subsequent 7 days, blood sam pies were taken daily to follow the post treatment return of lipoproteins and fibrinogen to their baseline levels. The fractional catabolic rates (FCRs) of LDL, Lp(a) and fibrinogen were caIculated as described by Apstein et al. [lI] . This caIculation model was used under the assumption that the synthesis and FCR of lipoproteins are not affected by rapid changes in the pool size [11, 14] . The plasma volume was taken as 4'5% of body weight. The pool size was caIculated by multiplying the plasma concentration with the plasma volume. The synthetic rate was estimated as the product of FCR and plasma pool size expressed per kilogram of body weight [15] .
Apo B-containing lipoproteins with phosphotungstate/MgClz. The apoproteins Band AI, as weil as fibrinogen, were quantified by rate nephelometry using commercial antibodies from Behring (Marburg, Germany).
Plasma viscosity was determined by capillary viscometry [12] . LDL receptor activity was assayed in cultured skin fibroblasts as described previously [13] .
Results
Plasma protein and lipoprotein concentrations in the patient during the cIinical phase of nephrotic syndrome and after improvement of the renal function are presented in Table I Plasma triglycerides were slightly increased to 219 mg dL-I (2'5mmoIL-l), whereas the VLDL-and HDLcholesterol levels were within the normal range. Plasma albumin concentration was decreased (2'15gdL-I) and urinary protein loss was 6-4gday-l. LDL receptor activity in cultured skin fibroblasts of the patient and his family was similar to normolipidaemic control subjects. With the normalization of hypoalbuminaemia and proteinuria, the plasma Lp Factors for conversion to SI units: 1 F = 0·0256 (mmol VI). 2F = 0·0113 (mmol L -I). 3 F = 10 (g L -I). 4 F = 29·4 (jtmol VI). Table 4 . Turnover data calculated from reaccumulation control and FH heterozygote were similar, but the ACR for LDL in the nephrotic patient was reduced. The FCR for Lp(a) in the nephrotic patient was reduced in comparison to the normolipidaemic control as weil as the FH heterozygote patient, whereas ACR for Lp(a) in the nephrotic patient was increased. This can probably be explained on the basis of a shift of apolipoprotein B towards increased Lp(a) rather than LDL production. Although the absolute synthesis rate of fibrinogen in the nephrotic patient was increased, the FCR was similar to those in the nonnephrotic hypercholesterolaemic patient. As plasma Lp(a) and fibrinogen levels remained elevated even I year after clinical improvement in the nephrotic syndrome, we started regular HELP treatment at weekly intervals. The average interval concentrations between two treatments of LDL-cholesterol, Lp(a) and fibrinogen are now maintained at 60 mgdL -I, 85mgdL-I, and 215mgdL-I respectively.
Discussion
Mechanisms causing hyperlipidaemia in patients with nephrotic syndrome are still unclear. Increased plasma LDL concentrations in nephrotic patients have been attributed to either overproduction or decreased catabolism, or both [15] [16] [17] . Furthermore, in vitra studies have demonstrated that altered lipid protein composition of LDL (i.e. triglyceride-rich core) are poor ligands for LDL receptors. Such triglyceride-rich lipoprotein particles are a regular feature of these patients and may explain their decreased catabolic rate. It has also been reported that nephrotic patients have reduced renal clearance of plasma mevalonate, a metabolite reported to suppress the LDL receptor activity. A reduced renal clearance of plasma mevalonate, which has been reported in these patients, may increase hepatic intracellular sterols and thereby suppress LDL receptor activity [16] . However, studies on FCRs in nephrotic patients are controversial because some studies report normal clearance of LDLs whereas others report reduced clearance in nephrotic patients [15, 16] .
Our nephrotic syndrome patient had elevated total plasma cholesterol but normal VLDL-and HDLcholesterol levels. Both the plasma LDL-cholesterol and triglycerides were in the upper range for normolipidaemic healthy controls. However, his plasma Lp(a) levels and fibrinogen values were over 15-fold and two-fold higher than the normal healthy controls. There are only a few studies that report Lp(a) levels in patients with nephrotic syndrome. In arecent study, 9 from a total of ll patients with primary nephrotic syndrome displayed elevated Lp(a) levels [4] . No correlation between Lp(a) concentration and proteinuria, hypoalbuminaemia, LDL-cholesterol and Lp(a) size polymorphism could be established.
The plasma Lp(a) concentration in our nephrotic patient is to our knowledge the highest reported in the literature so far. After clinical improvement in the nephrotic syndrome, Lp(a) concentrations decreased from 470 mg dL -I to 169 mg dL -I. This decrease was associated with a constant elevation of serum albumin. Analysis of apo(a) isoforms in the patient and his daughter revealed that both shared a common allele 10, wh ich was responsible for the elevated Lp(a) levels in the daughter. The other alleles, 19 in the father and 16 in the daughter, are unlikely to cause an increase in Lp(a). Comparing the Lp(a) concentrations of our patient with his daughter, the presence of allele 10 does not explain his extremely high Lp(a) levels. It thus appears that this elevation is secondary and may result from the nephrotic syndrome. However, it is worth noting that even I year after the improvement in his nephrotic symptoms the Lp(a) values remained twofold high er than in his daughter. This difference cannot solely be explained on the basis of apo(a) genotype.
Consequently as a therapeutic strategy, elevated Lp(a) and fibrinogen levels should both be normalized in patients with nephrotic syndrome and small apo(a) isoforms. For this purpose, extracorporeal HELP apheresis is the only promising regimen available at present.
